Director Biostatistics

The Director of Biostatistics is a hands‑on statistical leader responsible for the design, analysis, and interpretation of Phase 1–Phase 3 clinical trials with a primary focus on inflammation and oncology indications. This role combines scientific leadership with active execution and intensive CRO oversight, ensuring high‑quality statistical deliverables across outsourced clinical studies. The Director will work closely with Clinical Development and external partners to drive trial design, analysis strategies, and regulatory‑ready outputs while remaining directly involved in study‑level statistical activities. Responsibilities Statistical Leadership Lead and personally contribute to statistical strategy and execution for Phase 1–3 clinical studies, including first‑in‑human, dose‑escalation, proof‑of‑concept, and registrational trials in oncology and inflammatory diseases. Provide direct input into trial design, endpoint selection, sample size justification, interim analyses, and adaptive strategies, particularly for early‑stage development. Author, review, and approve: Statistical sections of clinical protocols. Statistical Analysis Plans (SAPs). Tables, listings, and figures (TLFs). Clinical Study Reports (CSRs). CRO Oversight & Execution Serve as the primary statistical point of contact for CROs, providing close, day‑to‑day oversight of outsourced biostatistics and programming activities. Actively review CRO deliverables for scientific accuracy, consistency, and regulatory compliance, including datasets, analysis outputs, and reports. Ensure CROs adhere to agreed‑upon timelines, quality standards, CDISC/CDASH conventions, and statistical methodologies. Lead CRO selection, scope definition, and ongoing performance management for biostatistics and programming services. Cross‑Functional & Regulatory Engagement Partner closely with Clinical Development to ensure statistical approaches align with program objectives and clinical strategy. Provide statistical expertise for data monitoring committees, interim analyses, and data review meetings. Contribute directly to regulatory submissions, briefing documents, and responses to health authority questions. Represent biostatistics in cross‑functional development teams and external regulatory interactions as needed. Operational Focus Ensure the timely production and accuracy of all statistical analyses and integrated reports across assigned studies. Maintain consistency of statistical approaches across programs while remaining flexible to study‑specific needs. Stay current on evolving statistical methodologies, regulatory expectations, and industry best practices relevant to oncology and inflammation trials. Statistical Programming Oversight Direct and mentor statistical programmers to ensure accurate, timely, and compliant production of CDISC‑compliant datasets (SDTM/ADaM), tables, listings, and figures (TLFs) for clinical study reports. Translate Statistical Analysis Plans (SAPs) into clear, actionable programming specifications and define data structure requirements for external CRO partners or internal teams. Ensure rigorous quality control (QC) and validation of analysis datasets and statistical outputs to meet FDA/EMA regulatory standards. Collaborate with data management and clinical teams to resolve data issues and ensure consistency between clinical databases and statistical outputs. Develop and implement efficient statistical programming workflows, macros, and best practices to improve productivity and compliance across multiple clinical trials. Qualifications PhD in Biostatistics, Statistics, Mathematics, Computer Science, or related field. 15+ years of experience supporting clinical drug development, including Phase 1–Phase 3 trials and regulatory submissions. Demonstrated experience working in CRO‑heavy models, with direct responsibility for reviewing and managing outsourced statistical work. Strong expertise in clinical trial statistics, regulatory standards (FDA, ICH), and industry best practices. Proficiency with SAS and other commonly used statistical software. Interested candidates should apply online with CV and cover letter in one document via our career portal located at Monte Rosa Therapeutics, Inc | Careers Center | Welcome. Monte Rosa Therapeutics (MRT) is a clinical‑stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI‑guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide‑ranging and differentiated target space of well‑validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. To learn more about MRTx, visit #J-18808-Ljbffr